StockNews.AI
AGIO
StockNews.AI
1 min

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

1. Pomerantz LLP is investigating potential securities fraud at Agios Pharmaceuticals. 2. Agios faces claims related to unlawful business practices and its leadership. 3. FDA delayed review of PYRUKYND® by three months, impacting investor confidence. 4. Agios's stock dropped 11.03% after the FDA announcement on September 4. 5. Investors may join the class action against Agios being led by Pomerantz.

3m saved
Insight
Article

FAQ

Why Bearish?

The investigation raises concerns about Agios's corporate governance and trustworthiness. Similar investigations in the past have led to significant stock declines, suggesting heightened market sensitivity towards this news.

How important is it?

Given active investigations and stock price decline, the potential for high volatility exists which may attract traders. Additionally, long-term implications could arise if the investigation leads to severe consequences.

Why Short Term?

The immediate fallout from the FDA delay and fraud allegations can influence the stock price quickly, as investor sentiment often reacts to news cycles more than fundamental changes over the long term.

Related Companies

AMGNBMYMRK
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Agios and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 4, 2025, Agios issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025.”   On news of the delayed review, Agios’s stock price fell $4.48 per share, or 11.03%, to close at $36.13 per share on September 4, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes.  CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News